On 12 July, 2011, the Medicines Patent Pool (MPP) announced an agreement with
Gilead Sciences for the licensing of its antiretroviral drugs tenofovir
disoproxil fumarate (TDF), emtricitabine (FTC), elvitegravir (EVG), cobisistat
(COBI) and a combination pill comprising all four drugs. The MPP, UNITAID and
several of the media have heralded the agreement as an important moment in
improving access to medicines in the developing world.
However, a
review of the licenses raise a number of serious issues that could impact the
access to medicines movement within the broader context of patent law reform
and trade policies.
In collaboration
with the International
Treatment Prepardeness Coalition (ITPC), an international coalition of
people living with HIV/AIDS devoted to advocacy on HIV/AIDS treatment access,
I-MAK has prepared a briefing paper which analyses the licenses and sets out
what the potential broader implications are to access and patients. The paper
also raises a number of pertinent questions about the role of the MPP and the
process under which the licenses were entered into. The Briefing Paper